Stem cell transplantation outcomes in lymphoblastic lymphoma

Jonathan E. Brammer, Issa Khouri, David Marin, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Richard E. Champlin, Chitra Hosing, Partow Kebriaei

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Lymphoblastic lymphoma (LBL) is an aggressive lymphoma pathologically similar to lymphoblastic leukemia, but primarily presents with nodal or extra-medullary involvement. The aim of this study is to describe outcomes of patients undergoing stem cell transplantation (SCT) for LBL compared to historical data. Thirty-nine patients, of which 54% lacked complete remission (CR), received SCT for LBL between 1990 and 2015; 31 allogeneic and eight autologous. Overall survival (OS) and progression free survival (PFS) at three years for the entire cohort was 41%, the cumulative incidence (CI) of non-relapse mortality (NRM) was 18% at one year, and CI relapse mortality was 28% at one-year and 36% at three years; results similar to historical reports. On multivariate analysis, the use of total-body irradiation (TBI) based conditioning and transplantation in CR were independently predictive of OS and PFS. For patients requiring SCT for LBL, CR and TBI-based conditioning prior to allogeneic SCT may provide improved disease control.

Original languageEnglish (US)
Pages (from-to)366-371
Number of pages6
JournalLeukemia and Lymphoma
Volume58
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Allogeneic stem cell transplantation
  • autologous stem cell transplantation
  • clinical results
  • lymphoblastic lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

MD Anderson CCSG core facilities

  • Clinical and Translational Research Center

Fingerprint

Dive into the research topics of 'Stem cell transplantation outcomes in lymphoblastic lymphoma'. Together they form a unique fingerprint.

Cite this